S- 1 Capsule Generic Name Trade Name Weikangda Capsule English Name TS- 1 Ingredients This product is a compound preparation, and its ingredients are tegafur, jimpamine and potassium oteracil. Properties This product is a hard capsule, and its contents are white or white-like particles or fine powder. Pharmacological effect 1, anti-tumor effect S-Gio capsule (Weikangda capsule) on Yoshida's sarcoma, AH- 130 ascites liver cancer, Sato's lung cancer (rats), S- 180 sarcoma, Lewis lung cancer, Colon26 (mice), human gastric cancer, colorectal cancer, and so on. 2. Mechanism of action: This product is a compound preparation consisting of tegafur, jimpamine and potassium oteracil. After oral administration, tegafur is slowly transformed into 5-FU in vivo, thus playing an anti-tumor role. The main toxic target organ in toxicology research is bone marrow hematopoietic stem cells. Indications of unresectable locally advanced or metastatic gastric cancer. Usage and dosage: 1. Single dose: The reference dose (1 dose) of the first dose for adults is calculated according to the surface area below, twice a day, 1 time after breakfast and dinner, for 28 days, and repeated every 14 days. Body surface area (square meters), China's formula for calculating body surface area is S=0.006 1× height +0.0 124× weight -0.0099. Where s represents the body surface area in m2; H stands for height, in centimeters; W represents the weight in kg. The first dose of S- 1 capsule (calculated by tegafur) is 40mg for patients with body surface area less than 1.25m2; Patient's body surface area 1.25m2- 1.5m2, 50mg each time; Patients with body surface area greater than 1.5m2, 60mg each time; The dose can be increased or decreased according to the patient's condition, and the dose is set at 40, 50, 60 and 75mg/ time. When the dosage needs to be increased, if there are no abnormal clinical examination values (hematological examination, liver and kidney function examination) and digestive tract symptoms related to this product, and there is no safety problem, the dosage can be increased one time in turn according to the reference amount, but the maximum dosage shall not exceed 75mg/ time; When reducing the dose, reduce one dose in turn according to the reference amount, and the minimum dose is 40mg/ time. 2. Combined medication: oral administration of S- 1 capsule 80mg/m2/ day, twice a day, respectively, after breakfast and dinner 1 time, for a total of 14 days, and withdrawal for 7 days; Cisplatin: 75mg/m2, intravenous drip for three days (day 1, day 2, day 3). Every 3 weeks is 1 cycle, and at least 2 cycles should be treated. Taboo 1, patients with severe allergic history to this product. 2. Patients with severe myelosuppression (which may aggravate symptoms). 3. Patients with severe renal insufficiency. 4. Patients with severe liver dysfunction. 5. Patients who are using other fluorouracil antineoplastic drugs (including combined chemotherapy with these drugs). 6. Patients who are using fluorocytosine. Pregnant women and lactating women use 1, and pregnant women and women of childbearing age are prohibited from using this product. 2. Breast-feeding women should stop breastfeeding if they need medical treatment. The safety of this product for infants, newborns, infants and low birth weight infants has not been determined. Generally speaking, most elderly people have low physiological function, so we should observe the patient's condition and use this product with caution. Store at room temperature and seal. Packaging: aluminum-plastic packaging. 1, 20mg specifications (based on tegafur): 42 capsules/box; 2, 25mg specifications (based on tegafur): 36 capsules/box; two-year validity 1, 20mg specifications; each capsule contains tegafur 20mg, jimpamine 5.8mg and potassium oteracil19.6.